Ramon Ravelo
Addiction Medicine · New York, NYNPI 1437172426
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.5% of the total across 573 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,033, 2.9 times the $1,044 reported in 2019. Among addiction medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 573 payments — averaging $22.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$3K
- Axsome Therapeutics, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Vanda Pharmaceuticals Inc.$938
- plus $2K from 10 others
What the payments were for
- Food & beverage$12,09594%
- Education$8366%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 156 | $2,873 |
| Teva Pharmaceuticals USA, Inc. | 89 | $2,576 |
| Axsome Therapeutics, Inc. | 32 | $1,502 |
| Otsuka America Pharmaceutical, Inc. | 61 | $1,298 |
| Alkermes, Inc. | 69 | $1,273 |
| Vanda Pharmaceuticals Inc. | 35 | $938 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $737 |
| Lundbeck LLC | 38 | $521 |
| Sunovion Pharmaceuticals Inc. | 16 | $328 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $307 |
| Neurocrine Biosciences, Inc. | 9 | $218 |
| Bausch Health US, LLC | 9 | $171 |
| E.r. Squibb & Sons, L.L.C. | 3 | $72 |
| Validus Pharmaceuticals LLC | 3 | $69 |
| Johnson & Johnson | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,930 in reported general payments places this provider in the 90th percentile of 125 addiction medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 317 | $169,026 |
| RexultiBrexpiprazole | 81 | $165,720 |
| VraylarCariprazine Hcl | 69 | $106,749 |
| AuvelityDextromethorphan Hbr/Bupropion | 63 | $41,583 |
| OzempicSemaglutide | 36 | $32,630 |
| CaplytaLumateperone Tosylate | 15 | $22,644 |
| Bupropion XlBupropion Hcl | 551 | $6,686 |
| Escitalopram Oxalate | 1,325 | $6,020 |
| Quetiapine Fumarate | 709 | $3,809 |
| Trazodone Hcl | 661 | $2,875 |
| Zolpidem Tartrate | 720 | $2,610 |
| Clonazepam | 619 | $2,280 |
| Aripiprazole | 178 | $2,238 |
| Memantine Hcl | 161 | $1,865 |
| Temazepam | 101 | $1,649 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $737 | $169,026317 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,298 | $165,72081 claims |
| AbbVieVraylar | $2,873 | $106,74969 claims |
| Axsome Therapeutics, Inc.Auvelity | $1,502 | $41,58363 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $307 | $22,64415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 125 addiction medicine providers in New York.
Other addiction medicine in New York
- John MarianiNew York$38K
- Stefan KantrowitzNew York$33K
- Stuart GitlowNew York$7K
- James WolbergNew York$5K
- Joshua LeeNew York$1K
- Lloyd ZimmermanNew York$1K
- Stephanie SeaslyNew York$829
- James McKnightNew York$694
- Elias DakwarNew York$514
- Alina BabarNew York$334
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.